The FDA has issued several cancer warnings and a cancer surveillance requirement for patients aged <30 treated with tumor necrosis factor (TNF) inhibitors (TNF-I), although the initial FDA report was criticized for methodological reasons [71,72,73,74,75]. This evidence concerns the gene TNF and cancer.